Murali Janakiram

5.1k total citations
92 papers, 1.5k citations indexed

About

Murali Janakiram is a scholar working on Oncology, Hematology and Immunology. According to data from OpenAlex, Murali Janakiram has authored 92 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 33 papers in Hematology and 33 papers in Immunology. Recurrent topics in Murali Janakiram's work include CAR-T cell therapy research (23 papers), Multiple Myeloma Research and Treatments (19 papers) and T-cell and Retrovirus Studies (12 papers). Murali Janakiram is often cited by papers focused on CAR-T cell therapy research (23 papers), Multiple Myeloma Research and Treatments (19 papers) and T-cell and Retrovirus Studies (12 papers). Murali Janakiram collaborates with scholars based in United States, China and India. Murali Janakiram's co-authors include Xingxing Zang, Jordan M. Chinai, Aimin Zhao, Joseph A. Sparano, Urvi A. Shah, Weifeng Liu, Mark Schoenberg, Haiying Cheng, Wantao Chen and Fuxiang Chen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Murali Janakiram

84 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Murali Janakiram United States 18 969 734 249 196 174 92 1.5k
Diann Blanset United States 14 950 1.0× 719 1.0× 379 1.5× 153 0.8× 143 0.8× 30 1.6k
Paulo Vidal Campregher Brazil 12 569 0.6× 950 1.3× 323 1.3× 112 0.6× 429 2.5× 57 1.7k
Patrizia Leone Italy 27 723 0.7× 711 1.0× 675 2.7× 263 1.3× 360 2.1× 65 2.0k
Keturah Brown United States 6 1.2k 1.2× 1.4k 1.9× 253 1.0× 185 0.9× 44 0.3× 8 2.0k
Kathryn A. Kolquist United States 12 467 0.5× 449 0.6× 634 2.5× 199 1.0× 188 1.1× 20 1.5k
Joë-Marc Chauvin United States 10 1.3k 1.3× 1.3k 1.7× 326 1.3× 157 0.8× 51 0.3× 16 1.8k
Sonia Pastor France 14 857 0.9× 946 1.3× 229 0.9× 96 0.5× 40 0.2× 22 1.4k
José C. Villasboas United States 18 722 0.7× 488 0.7× 172 0.7× 79 0.4× 83 0.5× 127 1.3k
Amer Assal United States 10 591 0.6× 433 0.6× 203 0.8× 157 0.8× 84 0.5× 32 941
Hans‐Jürgen Gruss Germany 16 547 0.6× 528 0.7× 159 0.6× 256 1.3× 66 0.4× 21 1.4k

Countries citing papers authored by Murali Janakiram

Since Specialization
Citations

This map shows the geographic impact of Murali Janakiram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murali Janakiram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murali Janakiram more than expected).

Fields of papers citing papers by Murali Janakiram

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murali Janakiram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murali Janakiram. The network helps show where Murali Janakiram may publish in the future.

Co-authorship network of co-authors of Murali Janakiram

This figure shows the co-authorship network connecting the top 25 collaborators of Murali Janakiram. A scholar is included among the top collaborators of Murali Janakiram based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murali Janakiram. Murali Janakiram is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Banerjee, Rahul, Mengru Wang, Xiaoliang Wang, et al.. (2025). Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis. Blood Cancer Journal. 15(1). 48–48. 1 indexed citations
2.
Kumar, Nathella Pavan, Arul Nancy, Murali Janakiram, et al.. (2025). Acute-phase proteins as biomarkers of inflammation in HIV patients with latent tuberculosis: a prospective study. Frontiers in Immunology. 16. 1551775–1551775.
3.
Alsina, Melissa, Binod Dhakal, Jeremy Pantin, Carol Ann Huff, & Murali Janakiram. (2025). Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable. Future Oncology. 21(10). 1137–1144. 1 indexed citations
4.
Keesari, Praneeth Reddy, et al.. (2025). Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies. Current Hematologic Malignancy Reports. 20(1). 3–3. 1 indexed citations
5.
Htut, Myo, et al.. (2024). Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen. Frontiers in Immunology. 15. 1444010–1444010. 5 indexed citations
6.
Goldsmith, Scott, Geoffrey Shouse, F. Lennie Wong, et al.. (2024). Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy. Transplantation and Cellular Therapy. 30(9). 927.e1–927.e9. 5 indexed citations
7.
Goldsmith, Scott, Geoffrey Shouse, F. Lennie Wong, et al.. (2023). Clonal Hematopoiesis Is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. Blood. 142(Supplement 1). 4814–4814.
8.
Castagna, Francesco, Lili Zhang, James M. Tauras, et al.. (2023). Global Longitudinal Strain Is Associated with Mortality in Patients with Multiple Myeloma. Journal of Clinical Medicine. 12(7). 2595–2595. 1 indexed citations
9.
Cliff, Edward R. Scheffer, Murali Janakiram, & Aaron S. Kesselheim. (2023). Melflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee. The Lancet Haematology. 10(5). e314–e317. 3 indexed citations
10.
Bashir, Qaiser, Marc Braunstein, Murali Janakiram, et al.. (2023). Overcoming Barriers to Autologous Stem Cell Transplantation in Multiple Myeloma: Recommendations from a Multidisciplinary Roundtable Discussion. Transplantation and Cellular Therapy. 29(11). 666–673. 7 indexed citations
11.
Janakiram, Murali, Nivedita Arora, Veronika Bachanová, & Jeffrey S. Miller. (2021). Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma. Transplantation and Cellular Therapy. 28(2). 61–69. 2 indexed citations
12.
Carlo‐Stella, Carmelo, Pier Luigi Zinzani, Murali Janakiram, et al.. (2021). Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma (LOTIS-3). Blood. 138(Supplement 1). 54–54. 14 indexed citations
13.
14.
Chung, Elaine Y., Urvi A. Shah, Yongqiang Wei, et al.. (2019). PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma. Clinical Cancer Research. 25(12). 3589–3601. 17 indexed citations
15.
Shah, Urvi A., Beamon Agarwal, Aditi Shastri, et al.. (2018). Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure. Case Reports in Oncological Medicine. 2018. 1–6.
16.
Derman, Olga, Qiang Liu, Hatef Massoumi, et al.. (2017). Ibrutinib‐induced severe liver injury. Clinical Case Reports. 5(6). 735–738. 10 indexed citations
17.
Janakiram, Murali, et al.. (2017). An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer. Applied immunohistochemistry & molecular morphology. 26(9). 611–619. 24 indexed citations
18.
Assal, Amer, Olga Derman, Noah Kornblum, et al.. (2016). Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy. Oncotarget. 7(32). 51981–51990. 29 indexed citations
19.
Janakiram, Murali, Jordan M. Chinai, Aimin Zhao, Joseph A. Sparano, & Xingxing Zang. (2015). HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. OncoImmunology. 4(8). e1026534–e1026534. 94 indexed citations
20.
Janakiram, Murali, Jordan M. Chinai, Susan Fineberg, et al.. (2014). Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. Clinical Cancer Research. 21(10). 2359–2366. 131 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Diann Blanset Breakdown of academic impact, for papers by Paulo Vidal Campregher Breakdown of academic impact, for papers by Patrizia Leone Breakdown of academic impact, for papers by Keturah Brown Breakdown of academic impact, for papers by Kathryn A. Kolquist Breakdown of academic impact, for papers by Joë-Marc Chauvin Breakdown of academic impact, for papers by Sonia Pastor Breakdown of academic impact, for papers by José C. Villasboas Breakdown of academic impact, for papers by Amer Assal Breakdown of academic impact, for papers by Hans‐Jürgen Gruss
Rankless by CCL
2026